中低收入国家2型糖尿病成人卫生系统干预的系统综述与荟萃分析
该研究系统检索并荟萃分析了中低收入国家针对2型糖尿病成人的卫生系统干预随机对照试验,共纳入39项研究、21080名参与者。HbA1c荟萃分析显示总体平均差异为-0.46%,药师任务分担干预效果最显著(-0.87%),多组分诊所干预证据确定性为中等。非血糖结局数据稀少,农村和低收入国家研究不足。
要点
- 卫生系统干预可改善中低收入国家2型糖尿病患者的血糖控制,总体HbA1c平均差异-0.46%。
- 药师任务分担干预的HbA1c降幅最大(-0.87%),其次为多组分诊所干预(-0.37%)。
- 非血糖结局(死亡率、生活质量、成本效果)数据稀少,农村和低收入国家研究不足。
核心结论
- 卫生系统干预可能有效改善中低收入国家2型糖尿病患者的血糖控制,但农村和低收入国家研究不足。
- 多组分诊所干预在各类干预中血糖获益证据最强,但证据确定性仅为中等。
研究设计与样本
- 系统综述与荟萃分析,检索Ovid MEDLINE、Cochrane Library、EMBASE等数据库至2020年2月24日。
- 纳入39项随机对照试验(19项整群RCT,20项个体RCT),总参与者21080人,HbA1c荟萃分析纳入10060人(考虑整群设计效应)。
主要发现
- HbA1c总体平均差异为-0.46%(95%CI -0.60%至-0.31%,I2 87.8%,p<0.001)。
- 多组分诊所干预HbA1c平均差异-0.37%(95%CI -0.64%至-0.10%,I2 60.0%,n=7,p=0.020)。
- 药师任务分担研究HbA1c平均差异-0.87%(95%CI -1.20%至-0.53%,I2 91.0%,n=13,p<0.001)。
- 单独糖尿病教育或支持试验HbA1c平均差异-0.27%(95%CI -0.50%至-0.04%,I2 64.1%,n=7,p=0.010)。
- 死亡率、健康相关生活质量和成本效果数据稀少,无法定量合并。
关键数值与推荐
- 纳入标准:中低收入国家成人2型糖尿病卫生系统干预的RCT,报告血糖变化、死亡率、生活质量或成本效果至少一项。
- 血糖控制证据确定性:多组分诊所干预为中等,其他干预类型为低或极低。
- 偏倚风险:8项研究低风险,15项 unclear,16项高风险(针对血糖控制总结评估)。
临床怎么用
- 在中低收入国家可优先考虑药师任务分担和多组分诊所干预以改善血糖控制。
- 单独糖尿病教育或支持也有一定血糖获益,但效应较小。
- 非血糖结局证据不足,临床决策需结合当地资源和实施条件。
局限性
- 缺乏卫生系统干预的共识定义。
- 纳入研究质量存在差异。
- 非血糖结局数据稀少,农村和低收入国家研究不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Effective health system interventions may help address the disproportionate burden of diabetes in low- and middle-income countries (LMICs). We assessed the impact of health system interventions to improve outcomes for adults with type 2 diabetes in LMICs. METHODS AND FINDINGS: We searched Ovid MEDLINE, Cochrane Library, EMBASE, African Index Medicus, LILACS, and Global Index Medicus from inception of each database through February 24, 2020. We included randomized controlled trials (RCTs) of health system interventions targeting adults with type 2 diabetes in LMICs. Eligible studies reported at least 1 of the following outcomes: glycemic change, mortality, quality of life, or cost-effectiveness. We conducted a meta-analysis for the glycemic outcome of hemoglobin A1c (HbA1c). GRADE and Cochrane Effective Practice and Organisation of Care methods were used to assess risk of bias for the glycemic outcome and to prepare a summary of findings table. Of the 12,921 references identified in searches, we included 39 studies in the narrative review of which 19 were cluster RCTs and 20 were individual RCTs. The greatest number of studies were conducted in the East Asia and Pacific region (n = 20) followed by South Asia (n = 7). There were 21,080 total participants enrolled across included studies and 10,060 total participants in the meta-analysis of HbA1c when accounting for the design effect of cluster RCTs. Non-glycemic outcomes of mortality, health-related quality of life, and cost-effectiveness had sparse data availability that precluded quantitative pooling. In the meta-analysis of HbA1c from 35 of the included studies, the mean difference was -0.46% (95% CI -0.60% to -0.31%, I2 87.8%, p < 0.001) overall, -0.37% (95% CI -0.64% to -0.10%, I2 60.0%, n = 7, p = 0.020) in multicomponent clinic-based interventions, -0.87% (-1.20% to -0.53%, I2 91.0%, n = 13, p < 0.001) in pharmacist task-sharing studies, and -0.27% (-0.50% to -0.04%, I2 64.1%, n = 7, p = 0.010) in trials of diabetes education or support alone. Other types of interventions had few included studies. Eight studies were at low risk of bias for the summary assessment of glycemic control, 15 studies were at unclear risk, and 16 studies were at high risk. The certainty of evidence for glycemic control by subgroup was moderate for multicomponent clinic-based interventions but was low or very low for other intervention types. Limitations include the lack of consensus definitions for health system interventions, differences in the quality of underlying studies, and sparse data availability for non-glycemic outcomes. CONCLUSIONS: In this meta-analysis, we found that health system interventions for type 2 diabetes may be effective in improving glycemic control in LMICs, but few studies are available from rural areas or low- or lower-middle-income countries. Multicomponent clinic-based interventions had the strongest evidence for glycemic benefit among intervention types. Further research is needed to assess non-glycemic outcomes and to study implementation in rural and low-income settings.
引用
- Flood D, Hane J, Dunn M, et al. Health system interventions for adults with type 2 diabetes in low- and middle-income countries: A systematic review and meta-analysis. PLoS Med. 2020. PMID: 33180775. doi:10.1371/journal.pmed.1003434
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。